Unlike classical microvascular complications, large-vessel atherosclerosis can precede the development of diabetes, suggesting that rather than atherosclerosis being a complication of diabetes, both conditions have common genetic and environmental antecedents, i.e., they spring from a "common soil." It is now known that adverse environmental conditions, perhaps related to less-thanoptimal nutrition, in fetal and early life are associated with an enhanced risk of both diabetes and cardiovascular disease many decades later. These same adverse environmental conditions are also associated with the development in adult life of abdominal obesity and the insulin-resistance syndrome (IRS). The IRS consists of glucose intolerance, hyperinsulinemia, dyslipidemia (high triglyceride and low high-density lipoprotein [HDL] cholesterol levels), and hypertension. Although the mechanism underlying this cluster is controversial, the statistical association is well established. All of the elements of the IRS have been documented as risk factors for type I1 diabetes. Some, but not all, of these elements are also cardiovascular disease risk factors, in particular, hypertension and low HDL cholesterol. Other factors associated with the IRS that may enhance cardiovascular disease risk are plasminogen activator inhibitor 1 and small, dense low-density lipoprotein particles. Whether insulin itself is a risk factor remains controversial, but recent epidemiological evidence has been mostly negative. This question has marked clinical relevance because if the IRS enhances cardiovascular disease risk by virtue of its concomitant factors and not the hyperinsulinemia per ee, this would tend to alleviate concerns that intensive insulin management of type I1 diabetic subjects could enhance the risk of large-vessel atherosclerosis. Clinical trials are urgently needed to settle this point.
I
t seems reasonable to expect that a complication of a disease should not occur in the absence of the disease itself, nor should it precede the disease that it supposedly complicates. The microvascular complications of diabetes follow these straightforward rules. The macrovascular complications, however, do not. Large-vessel atherosclerotic disease clearly can occur in the absence of diabetes, and there is little doubt that it sometimes precedes it, although how often this occurs has not been well quantified. In 1984, Jarrett published an article entitled "Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease: chicken, egg, or neither?" (1) in which he speculated that both diabetes and cardiovascular disease shared common antecedents, rather than one being a complication of the other. Jarrett's reasoning was based primarily on the fact that the prevalence of cardiovascular disease was as high, or even higher, in patients with newly discovered diabetes as in those who had had diabetes for a long time. Not only that, but it was equally high in individuals who did not have diabetes at all but were merely at increased risk of diabetes, i.e., individuals with impaired glucose tolerance (1, 2) . The latter group obviously constitutes a pool from which can appear diabetic patients whose macrovascular complications preceded their diabetes. Two recent developments have added further credence to the notion that both cardiovascular disease and diabetes share common genetic and environmental antecedents, i.e., that they spring from a "common soil."
In the U.K., Barker and Osmond (3) noted that those geographic regions that had suffered from high rates of infant mortality 50 or more years ago tended to exhibit high rates of a number of chronic diseases, among them diabetes and cardiovascular disease, many decades later (3). These findings suggested that whatever adverse conditions had been responsible for the high infant mortality produced longlasting consequences that contributed to chronic diseases in adult life among those who survived the adverse conditions of their early life. Later, it was shown that low birth weight and low rates of weight gain in the first year of life wete risk factors for hypertension (41, diabetes (431, and cardiovascular disease (6) in adult life. It was suggested that less-thanoptimal nutrition during fetal and early life could have long-term adverse consequences that could contribute to various adult diseases (7) . For example, it was hypothesized that impaired development of the endocrine pancreas in individuals who manifest the IRS are obese and, more particularly, exhibit abdominal obesity. Controversy has arisen over whether insulin resistance is really the cause of the syndrome, particularly of hypertension, and this controversy has been reviewed elsewhere (9) . In this report, I will focus primarily on the statistical associations between the various elements of the syndrome, since these are widely accepted.
The two developments described above are tied together by the observation that low birth weight is a risk factor for the IRS in adult life. This observation, originally made in the U.K. (4), has recently been confirmed by our group in a biethnic population in San Antonio, Texas, consisting of Mexican-Americans and non-Hispanic Caucasians (10) (Fig.  1) . The San Antonio study also documented that low birth weight was a risk factor for the later development of abdominal obesity. If it is the case that impaired fetal andlor infant nutrition limits the development of adipocytes, perhaps visceral adipocytes undergo hypertrophy more readily than adipocytes from other fat depots and thus become the storage sites of choice when total adipocyte capacity is limited. In any case, these findings are relevant to the present early life might predispose an individual to eventual P-cell theme, because, as will be discussed below, abdominal failure and type I1 diabetes (7) . It should be noted that this adiposity is a risk factor for both type I1 diabetes and hypothesis implies an islet cell failure model for type I1 cardiovascular disease and, hence, potentially part of the diabetes, a topic that will be discussed in more detail. It is common soil. also possible that early nutritional deficiencies could limit
To what extent can we defend the proposition that the IRS the development of adipocytes, so that when challenged with constitutes the common soil that underlies both type I1 excess calories in later years, individuals with limited num-diabetes and cardiovascular disease? All of the elements of bers of adipocytes and possibly with impaired ability to the IRS are consistent predictors of type I1 diabetes in differentiate new adipocytes would tend to experience hy-prospective studies. The evidence for this statement is pertrophy of their available adipocytes, leading to adverse summarized in Table 1 . (As will be demonstrated, the evimetabolic consequences.
dence in the case of cardiovascular disease is more mixed.) The second development that bolstered the common soil It hardly comes as a surprise that glucose intolerance and hypothesis was the description by Reaven, in his 1988 obesity are risk factors for type I1 diabetes. It is perhaps less Banting Lecture (8) , of what he called "Syndrome X," which well appreciated that dyslipidemia @gh triglyceride and low has also come to be known as the insulin-resistance syn-HDL levels) and hypertension, which are usually thought of drome (IRS). Although statistical correlations between the as consequences of diabetes, are also among its antecedents. various elements of the IRS had been well documented for Actually, the observation that hypertension precedes diabemany years, the unifying hypothesis Reaven put forward was tes has been in the diabetes literature for many years (17, 18) that tissue resistance to the action of insulin was the but has been largely neglected, perhaps because it lacked a underlying defect responsible for the other manifestations of theoretical rationale until Reaven identified it as part of the the syndrome. These manifestations included compensatory IRS. In an effort to develop optimal models for predicting hyperinsulinemia, glucose intolerance, hypertension, and diabetes, we noted that all such models contained represendyslipidemia, specifically hypertriglyceridemia and low high-tatives from the four major categories of IRS manifestations: density lipoprotein (HDL) cholesterol. Although not part of anthropometric, metabolic-carbohydrate, metabolic-lipid, Reaven's original description, it is apparent that most of the and hemodynamic (25). Interestingly, the ratio of waist to hip circumference, a measure of abdominal adiposity, was preferred to body mass index, a measure of overall adiposity, as a predictor of future diabetes (my unpublished observations).
Since, as indicated in Table 1 , insulin resistance has been directly shown to be a diabetes risk factor, it has become popular to interpret hyperinsulinemia, itself a diabetes risk factor, as a compensatory response to insulin resistance. In this scenario, the continual demand for insulin hypersecretion to maintain glucose homeostasis contributes to eventual islet cell exhaustion. Recently, these ideas have been challenged by the demonstration that much of the imrnunoassayable insulin in diabetic serum is not in fact insulin but rather proinsulin and other insulin precursors (26) . While this statement is undoubtedly true of patients with established diabetes, the situation in prediabetic individuals is less clear. Only recently have specific insulin imrnunoassays that distinguish between insulin and its biological precursors been used to study either confirmed (by prospective follow-up) or presumed prediabetic subjects. For example, our group has shown that the hyperinsulinemia that characterizes MexicanAmericans (27), a high-risk population for diabetes, is genuine (28) . Although proinsulin levels are elevated in this population, true hyperinsulinemia is also present, as documented by a specific insulin immunoassay, of which crossreactivity with proinsulin is only 0.2% (28) . Moreover, the elevation of proinsulin is not out of proportion with the insulin elevation, as shown by a normal insuhproinsulin ratio (28) . True hyperinsulinemia has also been demonstrated among subjects with impaired glucose tolerance (29), many of whom are prediabetic. Prospective studies, however, in two populations, Japanese-Americans (30) and elderly Finns (31), have suggested that proinsulin is a stronger risk factor for future diabetes than is insulin. Both of these studies had relatively short durations of follow-up, 5 and 4 years, respectively. It is possible that early in the course of the prediabetic process, true hyperinsulinemia predominates and that later the mix shifts progressively toward insulin precursors. None of this is to suggest that insulin resistance is not a bona fide precursor of diabetes. This phenomenon has been directly demonstrated by euglycemic insulin clamp studies of Pima Indians who were later followed for the development of diabetes (23) . Since clamp studies use exogenous insulin, the question of proinsulin does not arise. Thus, even if insulin deficiency develops earlier in the prediabetic process than was heretofore believed, it is still the case that insulin resistance, present at an even earlier stage, could have played a role in provoking the later islet cell failure. These considerations are relevant to the present discussion because of the postulated role of insulin as a risk factor not only for diabetes but also for cardiovascular disease. If the hyperinsulinemia seen in the IRS is really hyperproinsulinemia, the case for the IRS as a precursor of cardiovascular disease is weakened. Although it is possible to make a case that insulin is atherogenic (see below), this seems less plausible in the case of its biologically relatively inactive precursor molecules such as proinsulin.
The next question to address is whether the elements of the IRS (Table 1) are risk factors for cardiovascular disease as well as for diabetes. First, note that the three classical risk factors for cardiovascular disease are cholesterol, or more specifically low-density lipoprotein (LDL) cholesterol, cigarette smoking, and blood pressure. Of these, only blood pressure appears in Table 1 as a component of the IRS. Neither cholesterol nor cigarette smokmg has ever been documented as a risk factor for diabetes. Thus, we must concede at the outset that there is a major component of cardiovascular disease risk that is unrelated to the IRS and probably unrelated to diabetes as well. Apart from blood pressure, which is an established cardiovascular disease risk factor, the items listed in Table 1 can be divided into three categories: obesity-related; lipid-related; and insulin resistance-related.
Obesity is well established as a univariate risk factor for cardiovascular disease (32) (33) (34) , although there is controversy about whether it is an independent risk factor (34) . A more important question than whether a risk factor is independently related to a disease outcome is whether it plays a fundamental role in the pathogenesis of that disease. Even a risk factor that is involved in pathogenesis in an important way may disappear from a multivariate statistical model if the model contains other variables in the same causal pathway, especially if these other variables can be measured with greater precision than the risk factor of interest. There are also data from prospective epidemiological studies that indicate that the ratio of waist to hip circumference, a measure of abdominal adiposity, is a stronger cardiovascular disease risk factor than is body mass index, a measure of overall adiposity (35,36). As noted above, the same appears to be true of diabetes. Thus, diabetes and cardiovascular disease share not only obesity as a risk factor but, more specifically, its anatomic distribution.
HDL cholesterol is highly regarded as a cardiovascular disease risk factor (37, 38) , but the role of triglyceride as a cardiovascular disease risk factor has long been controversial (39) . The remarks in the preceding paragraph about the distinction between statistical independence and involvement in pathogenesis are pertinent to the case of triglyceride as well. Whatever the involvement of triglyceride in the pathogenesis of atherosclerosis, it is strongly correlated with lipid factors, which have a stronger claim to such involvement. Thus, it is strongly inversely correlated with the established cardiovascular disease risk factor HDL cholesterol. More recently, it has been observed to be strongly associated with a shift in the density spectrum of LDL cholesterol toward smaller, denser particles (40) (41) (42) , which are thought to be more atherogenic than ordinary LDL (43) (44) (45) . Small, dense LDL particles are more readily oxidized than ordinary LDL particles (46), a feature which may provide a theoretical mechanism for their enhanced atherogenicity because oxidized LDL is more atherogenic than native LDL (47) . Although small, dense LDL particles have been found to be associated with myocardial infarction and arteriographically documented coronary artery disease in cross-sectional studies (43-45), they have not been demonstrated to be a statistically significant independent risk factor for cardiovascular disease in prospective studies. Thus, the epidemiological data implicating small, dense LDL particles as a cardiovascular disease risk factor are no stronger than the data implicating triglyceride. Nevertheless, taken as a whole, the evidence suggests that the dyslipidemic pattern characteristic of the IRS signals an enhanced risk of largevessel atherosclerosis and its complications.
Finally, does insulin resistance and/or the compensatory hyperinsulinemia that it occasions add further to the in-creased cardiovascular disease risk associated with the IRS? There is much literature on animal and in vitro studies suggesting that insulin is atherogenic. This literature has been thoroughly reviewed by Stout (48) and will not be recapitulated here. In the mid-1980s, three prospective epidemiological studies suggested that insulin was an independent cardiovascular disease risk factor in men (49) (50) (51) . (Only one of the three studies included women [51] in whom insulin did not predict cardiovascular disease.) More recently, a number of negative prospective studies have a p peared (52) (53) (54) (55) (56) , including one that suggests that insulin is a cardiovascular disease risk factor only in men with the 312 apolipoprotein E phenotype (56) . Since there was no prior hypothesis specifying this subgroup result, it cannot be regarded as established until replicated in other studies. Thus, the evidence that insulin is a bona fide cardiovascular disease risk factor is, at best, mixed. In a recent series of articles on this topic, a consensus seemed to emerge that the IRS could be regarded as an antecedent of cardiovascular disease mainly because of its dyslipidemic and hemodynamic manifestation and not necessarily as a direct result of insulin resistance or hyperinsulinemia (57) (58) (59) (60) . As will be demonstrated, this idea has important clinical implications.
In addition, note that elevated levels of plasminogen activator inhibitor 1 (PAT-1) have also been associated with virtually all of the features of the IRS (61-67), including a direct demonstration of association with insulin resistance itself (65) . Because PAT-1 is thought to play a key role in the inhibition of fibrinolysis (63) and elevated levels of PAT-1 have been noted in myocardial infarction victims and individuals with arteriographically documented coronary artery disease (68) (69) (70) (71) , this association provides yet another theoretical mechanism whereby the IRS might contribute to the development of cardiovascular disease.
What does this summary of risk factors for type II diabetes and cardiovascular disease reveal about the common soil hypothesis? It is evident that there is not a complete overlap between the risk factors for the two diseases. Nevertheless, the weight of evidence seems to suggest that they share many antecedents.
We must acknowledge one contradictory piece of evidence that seems to go against the common soil hypothesis. It is well known that the Pima Indians, a population with the highest known rate of type I1 diabetes in the world (15), have a remarkably low rate of atherosclerotic disease (72) . Recent data from the Strong Heart Study (73), however, have established that this anomaly is not necessarily characteristic of all Native American populations. In the Strong Heart Study, Native Americans from three regions of the US.-North and South Dakota, Oklahoma, and Arizona-were studied (73) . All groups of Native Americans had high rates of type 11 diabetes, but concomitant low cardiovascular disease rates were observed only in Arizona (73) . Of possible relevance is the fact that the Caucasian genetic admixture, as judged by participant-reported grandparental ethnicity, was also lowest in Arizona (B.V. Howard, personal communication) . This suggests that the diabetescardiovascular disease link might somehow be a characteristic primarily of Caucasian populations. Compatible with this idea is the observation that rates of cardiovascular disease, at least among men, are intermediate in Mexican-Americans (75), another highrisk population for diabetes (76) , whose Caucasian genetic admixture is -60% (77), presumably higher than that among the Strong Heart Study participants. On the other hand, South Asians living in the U.K. have markedly high rates of both type I1 diabetes and cardiovascular disease (78) . Finally, even among Pima Indians, cardiovascular disease rates are higher in diabetic than in nondiabetic individuals (72) , suggesting that even when the soil is only minimally conducive to the development of cardiovascular disease, it nevertheless remains linked with diabetes.
What are the clinical implications of the IRS? With the recent publication of the Diabetes Complications and Control Trial (DCCT) results, which provided highly persuasive evidence that intensive insulin management can slow the onset and progression of microvascular complications in type I diabetic patients (79), the case for more intensive insulin management of type I1 diabetic patients becomes stronger. There are a number of caveats, however, which have been outlined in a position statement of the American Diabetes Association (80) . These include potentially more serious consequences of hypoglycemic episodes in type I1 patients, who tend to be older and are more likely to have significant comorbidity. Nevertheless, all other things being equal, a case can now be made for more liberal use of insulin in the management of type I1 diabetic patients. This impulse, however, runs up against the concern that such management might paradoxically increase the risk of cardiovascular disease in these patients. Thus, the question of whether the IRS enhances cardiovascular disease risk as a direct result of its hyperinsulinemia or, on the other hand, as a consequence of its other manifestations takes on considerable clinical importance. Only randomized clinical trials can provide a definitive answer to this question.
At present, there are only two completed clinical trials that bear on the question of whether therapy with exogenous insulin has the potential to increase cardiac risk. The first is the University Group Diabetes Program, in which -200 patients were randomly assigned to one of four treatment regimens: oral agent (tolbutamide); fixed dose insulin; variable dose i n s u , or placebo (81) . After 8 years of follow-up, neither of the insulin-treated groups showed excess cardiovascular mortality relative to the placebo group. In the DCCT, there was actually a 41% reduction in cardiovascular end points in the group receiving intensive insulin management (79) . This result was not statistically sigruficant, however, owing to the small number of such end points in this relatively young cohort of type I diabetic patients.
If these were the only data available, they would be reassuring. Unfortunately, a recent abstract on the pilot phase of the Veterans Administration Cooperative Study on Glycemic Control and Complications reported a less encouraging result in intensively managed type I1 diabetic patients. Of 153 patients after 27 months of follow-up, those who had received intensive insulin management experienced a twofold increase in cardiac end points (82) . Although the numbers were small, this difference nevertheless achieved borderline statistical significance (P = 0.09). Finally, the U.K. Prospective Study (83) , which has been under way for several years but has not yet reported results, has the potential of shedding further light on this vexing question.
At present, the balance of evidence suggests that exogenous insulin administration does not increase cardiac risk. In view of the importance of the question, however, it is essential that definitive clinical trials be conducted to resolve this issue. Note that although a large number of clinical trials have indicated that lowering of cholesterol can reduce the risk of cardiovascular disease, all of these trials have systematically excluded patients with diabetes. In view of their distinctive pattern of lipid abnormalities, there is a need for clinical trials on the proper management of dyslipidemia in diabetic patients.
